Mycoplasma Testing Market

PCR Technology A Market Leader for Mycoplasma Testing Asia Poised for Rapid Growth

Mycoplasma testing is extensively used in almost all important cell culture processes. The adoption rate for these products is very high and is expected to increase in future. The use of mycoplasma testing market will be boosted by the increasing research activities in drug discovery and life science technologies. These products are used for drug discovery by pharmaceutical and biotechnology companies.

Mycoplasma testing market is a research-driven market. R&D expenditure and number of biotechnology patterns are important indicators for this market. North America accounted for 37.74% of the global R&D spending in 2010. The U.S. alone accounted for 35.33% of all R&D spending in the world. According to estimates from the World Bank, the R&D spending in North America increased at a CAGR of 4.56% between 2001 and 2010.

On the other hand, Asia is expected to grow at a faster rate than any other region as R&D spending in this geographic segment increased from $158.94 Billion in 2001 to $329.31 Billion in 2010, at a CAGR of 8.43%. In 2010, Asia accounted for 27.13% of the global R&D spending. Moreover, R&D spending accounted for 1.97% of Asia’s GDP in 2010, which has a large scope for growth in the future. In this region, there is strong trend of successfully commercializing biotechnology research. The R&D spending in this regional segment increased from $12.59 Billion in 2001 to $104.32 Billion in 2010 at a CAGR of 26.48%. China has the highest growth rate for R&D spending between 2001 and 2010. The government in China is also undertaking various initiatives to promote genomics research. For instance, it is planning to invest more than $300 Billion in biotechnology between 2012 and 2017. Japan accounts for one of the largest R&D spending among all the regional segments in the Asian region. In 2010, Japan accounted for 14.75% of the global R&D spending. The R&D spending accounted for 3.16% of Japan’s GDP in 2010. Of all regional segments, Japan had the highest relative R&D spending in 2010.

According to the WIPO, in 2012, the number of biotechnology patent applications by residents in Asia stood at 9,063 and this region accounted for 52.47% of all biotechnology patent applications by residents in the world. This high focus on biotechnology research is another major factor driving the growth of the mycoplasma testing market in Asia.

Research in new drug launches and PCR technology in this area are new revenue pockets for players in the mycoplasma testing market.  Use of PCR for the detection of contaminations in cell cultures has become increasingly widespread due to its efficiency in sensitive, specific and long and complex procedures for mycoplasma testing. This technology is expected to grow at the highest CAGR between 2014 and 2019. The market is expected to be driven by increased research and development spending by biotechnology companies, government and public sector funding for research. In addition, new innovations have contributed to grow the market to a great extent.

Asia is growing faster in past few years and is expected to grow at the fastest rate in forecasted period. Emerging Asian countries such India, China and Japan are expected to have healthy growth in the coming five years, considering the huge R&D spending as well as growing technical know-how to increasing public funding.

North America accounted for the largest share of the global mycoplasma testing market in 2014 and Asia expected to grow at the highest CAGR in the forecast period for this report (2014–2019). North American & Asian countries are expected to witness a steady year-on-year growth, due to increase in demand for innovations in proteomics and genomic research. Moreover, an increase in healthcare budgets and R&D activities in this region will further fuel the demand for products offered in the mycoplasma testing market.

Related Reports:

Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Report Code
BT 3371
Published ON
Jun, 2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Mycoplasma Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved